NCT02205424: CANVAS

Cognition And Neocortical Volume After Stroke

Completed Last updated 10 June 2022

What this trial tests

trial in Ischaemic Stroke in 175 participants. Completed in 30 June 2021.

Timeline

1 May 2011

Primary endpoint
31 December 2020

30 June 2021

Quick facts

Lead sponsor	The Florey Institute of Neuroscience and Mental Health
Status	Completed
Study type	OBSERVATIONAL
Enrollment	175
Start date	1 May 2011
Primary completion	31 December 2020
Estimated completion	30 June 2021
Sites	3 locations across Australia

Conditions studied

• Ischaemic Stroke — all drugs for Ischaemic Stroke →
• Alzheimer's Disease — all drugs for Alzheimer's Disease →
• Vascular Dementia — all drugs for Vascular Dementia →

Sponsor

The Florey Institute of Neuroscience and Mental Health

Who can join

18 and older, any sex, with Ischaemic Stroke or Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stroke and dementia are two of the most common and disabling conditions worldwide, responsible for an enormous and growing burden of disease. There is increasing awareness that the two conditions are linked, with cognitive impairment and dementia common after stroke, vascular dementia accounting for about one-fifth of all dementia cases and recent evidence on the contribution of vascular risk factors to Alzheimer's disease. Yet little is known about whether brain volume loss - a hallmark of dementia - occurs after stroke, and whether such atrophy is related to cognitive decline. The aim of this research is to establish whether stroke patients have reductions in brain volume in the first three years post-stroke compared to control subjects, and whether regional and global brain volume change is associated with post-stroke dementia in order to elucidate potential causal mechanisms (including genetic markers, amyloid deposition and vascular risk factors). The hypotheses are that stroke patients will exhibit greater brain volume loss than comparable cohorts of stroke-free controls, and further, that stroke patients who develop dementia will exhibit greater global and regional brain volume loss than those who do not dement. An understanding of whether stroke is neurodegenerative, and in which patients, may be used to help guide the early delivery of disease-modifying therapies.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Dynamic Regional Brain Atrophy Rates in the First Year After Ischemic Stroke.
   Brodtmann A, Khlif MS, Egorova N, Veldsman M, et al · · 2020 · cited 67× · PMID 32772680 · DOI 10.1161/strokeaha.120.030256
2. Neurodegeneration Over 3 Years Following Ischaemic Stroke: Findings From the Cognition and Neocortical Volume After Stroke Study.
   Brodtmann A, Werden E, Khlif MS, Bird LJ, et al · · 2021 · cited 32× · PMID 34744989 · DOI 10.3389/fneur.2021.754204
3. Changes in White Matter Microstructure Over 3 Years in People With and Without Stroke.
   Egorova-Brumley N, Dhollander T, Khan W, Khlif MS, et al · · 2023 · cited 11× · PMID 36792378 · DOI 10.1212/wnl.0000000000207065
4. Weekend sedentary behaviour and cognition three months after stroke based on the exploratory analysis of the CANVAS study.
   Egorova-Brumley N, Khlif MS, Werden E, Johnson L, et al · · 2025 · PMID 40097532 · DOI 10.1038/s41598-025-93149-4